Department of Oncology, University & General Hospital, Udine, Italy.
Future Oncol. 2013 Nov;9(11):1687-91. doi: 10.2217/fon.13.189.
Although the median survival of patients with advanced disease has progressively increased, colorectal cancer remains a major worldwide health problem, with approximately 1 million new cases and 500,000 deaths every year. At the 2013 World Congress on Gastrointestinal Cancers, investigators have recently dealt with many clinically relevant questions, such as the preferred biologic drug to be used upfront in patients with KRAS wild-type colorectal tumors, the optimal treatment intensity, the most suitable maintenance strategy, the need for deeper molecular information when using EGFR inhibitors and the use of antiangiogenic drugs in the elderly. Briefly summarizing all the news coming from this moving landscape, this article focuses on the results of the major randomized Phase III trials presented at the meeting.
尽管晚期疾病患者的中位生存期逐渐延长，但结直肠癌仍然是一个全球性的主要健康问题，每年约有 100 万新发病例和 50 万例死亡。在 2013 年世界胃肠癌大会上，研究人员最近处理了许多临床相关问题，例如 KRAS 野生型结直肠肿瘤患者首选的生物药物、最佳治疗强度、最适合的维持策略、使用 EGFR 抑制剂时是否需要更深入的分子信息以及在老年人中使用抗血管生成药物。本文简要总结了从这个不断发展的领域中获得的所有消息，重点介绍了会议上提交的主要随机 III 期试验的结果。
